Thrombophilia screening yielded positive results in similar proportions of patients on rivaroxaban and VKA, including factor V Leiden (22.7 vs. 15.9%, p = 0.17), prothrombin G20210A (4.5 vs. 7.6%, p = 0.33) and deficiencies in natural anticoagulants (9.1 vs. 15.9%, p = 0.11), respectively. The gene discussed is F2; the disease is Rare hereditary thrombophilia.